Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats.
Diabetic nephropathy
Empagliflozin
Tubular injury markers
Journal
Indian journal of clinical biochemistry : IJCB
ISSN: 0970-1915
Titre abrégé: Indian J Clin Biochem
Pays: India
ID NLM: 8708303
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
18
03
2018
accepted:
10
09
2018
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
20
2
2020
Statut:
ppublish
Résumé
Empagliflozin, a SGLT-2 inhibitor, improves diabetic nephropathy through its pleiotropic anti-inflammatory effects. The present study aims to evaluate empagliflozin effects on renal and urinary levels of tubular epithelial cell injury markers in streptozotocin-induced diabetic rats. Empagliflozin at 10 mg/kg (p.o.) was administered for 4 weeks, beginning 8 weeks after induction of diabetes. Renal function as well as markers of renal tubular epithelial cell injury were assessed in kidney tissue homogenates and urine. Empagliflozin was able to ameliorate diabetes induced elevations in serum cystatin C levels. It also alleviated renal KIM-1/NGAL levels and urinary albumin, α-GST, and RBP excretions. In addition to decreasing urinary levels of cell cycle arrest indices i.e. TIMP-2 and IGFBP7, empagliflozin mitigated acetylated NF-κB levels in renal tissues of diabetic rats. As a whole, these findings reveal empagliflozin capability in improving diabetic nephropathy via ameliorating indices of renal inflammation, injury, and cell cycle arrest on streptozotocin-induced diabetic rats.
Identifiants
pubmed: 32071503
doi: 10.1007/s12291-018-0790-6
pii: 790
pmc: PMC6995469
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109-114Informations de copyright
© Association of Clinical Biochemists of India 2018.
Déclaration de conflit d'intérêts
Conflicts of interestNone of the authors declare any conflicts of interest.
Références
Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103
pubmed: 25470017
Horm Metab Res. 2015 Aug;47(9):686-92
pubmed: 25611208
Int J Clin Exp Med. 2015 Oct 15;8(10):18225-34
pubmed: 26770424
PLoS One. 2014 Jun 24;9(6):e100777
pubmed: 24960177
Diabetes Care. 2009 Nov;32(11):2068-74
pubmed: 19651921
Clin Kidney J. 2016 Jun;9(3):353-8
pubmed: 27274818
Scand J Clin Lab Invest. 1998 Nov;58(7):585-92
pubmed: 9890342
Curr Opin Nephrol Hypertens. 2015 Jan;24(1):21-7
pubmed: 25415614
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
Diabetes Care. 2011 Nov;34(11):2374-8
pubmed: 22025783
Physiol Rev. 2013 Jan;93(1):137-88
pubmed: 23303908
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Curr Med Chem. 2014;21(28):3244-60
pubmed: 25039784
PLoS One. 2016 Mar 14;11(3):e0150897
pubmed: 26974954
PLoS One. 2013;8(2):e54442
pubmed: 23390498
Sci Rep. 2016 May 26;6:26428
pubmed: 27226136
Nephrol Dial Transplant. 2012 Aug;27(8):3049-56
pubmed: 22734110
Nat Rev Nephrol. 2015 May;11(5):264-76
pubmed: 25643664
Kidney Int. 2011 May;79(10):1042-4
pubmed: 21527942
Crit Care Clin. 2015 Oct;31(4):621-32
pubmed: 26410133
N Engl J Med. 2009 Jan 8;360(2):129-39
pubmed: 19092145
Int J Immunopathol Pharmacol. 2015 Mar;28(1):129-33
pubmed: 25816416
J Diabetes Complications. 2012 Nov-Dec;26(6):546-53
pubmed: 22981148
Diabetes Care. 2016 Aug;39 Suppl 2:S165-71
pubmed: 27440829
J Am Soc Nephrol. 2010 Apr;21(4):556-63
pubmed: 20167701
Am J Physiol Renal Physiol. 2014 Aug 1;307(3):F317-25
pubmed: 24944269
Eur Heart J. 2018 Feb 1;39(5):363-370
pubmed: 29020355
N Engl J Med. 2013 Nov 14;369(20):1892-903
pubmed: 24206457